CL2013000685A1 - Compuestos derivados de n-(fenil/bencil)-6-(1,2,4-oxadiazol-3-il)-1,3,5-triazin-2,4-diamina; bloqueadores de los canales de sodio ( nav 1.7); composicion farmaceutica; que los comprende; uso en el tratamiento del dolor cronico. - Google Patents
Compuestos derivados de n-(fenil/bencil)-6-(1,2,4-oxadiazol-3-il)-1,3,5-triazin-2,4-diamina; bloqueadores de los canales de sodio ( nav 1.7); composicion farmaceutica; que los comprende; uso en el tratamiento del dolor cronico.Info
- Publication number
- CL2013000685A1 CL2013000685A1 CL2013000685A CL2013000685A CL2013000685A1 CL 2013000685 A1 CL2013000685 A1 CL 2013000685A1 CL 2013000685 A CL2013000685 A CL 2013000685A CL 2013000685 A CL2013000685 A CL 2013000685A CL 2013000685 A1 CL2013000685 A1 CL 2013000685A1
- Authority
- CL
- Chile
- Prior art keywords
- nav
- triazin
- oxadiazol
- understands
- diamine
- Prior art date
Links
- 208000000094 Chronic Pain Diseases 0.000 title 1
- 208000002193 Pain Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000006187 phenyl benzyl group Chemical group 0.000 title 1
- 239000003195 sodium channel blocking agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38215810P | 2010-09-13 | 2010-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000685A1 true CL2013000685A1 (es) | 2013-10-04 |
Family
ID=44651777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000685A CL2013000685A1 (es) | 2010-09-13 | 2013-03-13 | Compuestos derivados de n-(fenil/bencil)-6-(1,2,4-oxadiazol-3-il)-1,3,5-triazin-2,4-diamina; bloqueadores de los canales de sodio ( nav 1.7); composicion farmaceutica; que los comprende; uso en el tratamiento del dolor cronico. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8895733B2 (es) |
| EP (1) | EP2616465B1 (es) |
| JP (1) | JP2013537180A (es) |
| KR (1) | KR101843600B1 (es) |
| CN (1) | CN103221408A (es) |
| AU (1) | AU2011303978B2 (es) |
| BR (1) | BR112013005889A2 (es) |
| CA (1) | CA2812081A1 (es) |
| CL (1) | CL2013000685A1 (es) |
| CO (1) | CO6690768A2 (es) |
| CR (1) | CR20130111A (es) |
| CU (1) | CU20130036A7 (es) |
| DK (1) | DK2616465T3 (es) |
| EA (1) | EA026132B1 (es) |
| ES (1) | ES2559449T3 (es) |
| HR (1) | HRP20160094T1 (es) |
| HU (1) | HUE027256T2 (es) |
| MX (1) | MX2013002864A (es) |
| NZ (1) | NZ608116A (es) |
| PE (1) | PE20131377A1 (es) |
| PH (1) | PH12013500473A1 (es) |
| PL (1) | PL2616465T3 (es) |
| PT (1) | PT2616465E (es) |
| RS (1) | RS54544B1 (es) |
| SG (1) | SG188438A1 (es) |
| SI (1) | SI2616465T1 (es) |
| WO (1) | WO2012035023A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2616465T3 (da) * | 2010-09-13 | 2016-02-01 | Novartis Ag | Triazin-oxadiazoler |
| MX2014005304A (es) | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| CA2874621A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| PH12015501130B1 (en) | 2012-11-21 | 2023-01-27 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| CN105263490B (zh) | 2013-03-14 | 2018-05-22 | 基因泰克公司 | 取代的三唑并吡啶及其使用方法 |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| MX370588B (es) | 2013-08-30 | 2019-12-16 | Ptc Therapeutics Inc | Inhibidores de la bmi-1 de pirimidina sustituida. |
| US9975878B2 (en) | 2013-11-21 | 2018-05-22 | Ptc Therapeutics, Inc. | Substituted triazine BMI-1 inhibitors |
| US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
| JP6383418B2 (ja) | 2013-11-27 | 2018-08-29 | ジェネンテック， インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
| MA42118A (fr) | 2015-05-22 | 2018-03-28 | Genentech Inc | Benzamides substitués et leurs méthodes d'utilisation |
| WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP6987746B2 (ja) | 2015-09-28 | 2022-01-05 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| US10899732B2 (en) | 2015-11-25 | 2021-01-26 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| BR112019007763A2 (pt) | 2016-10-17 | 2019-07-02 | Genentech Inc | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção |
| EP3529245A4 (en) * | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| WO2019191702A1 (en) | 2018-03-30 | 2019-10-03 | F. Hoffmann-La Roche Ag | Substituted hydro-pyrido-azines as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| JP2021535198A (ja) | 2018-08-17 | 2021-12-16 | ピーティーシー セラピューティクス， インコーポレイテッド | 膵臓癌を治療する方法 |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| WO2021195360A1 (en) * | 2020-03-27 | 2021-09-30 | Landos Biopharma, Inc. | Plxdc2 ligands |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| WO2000075129A1 (en) | 1999-06-07 | 2000-12-14 | Shire Biochem Inc. | Thiophene integrin inhibitors |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| SI2256108T1 (sl) | 2002-07-18 | 2016-05-31 | Janssen Pharmaceutica N.V. | Substituirani triazinski kinazni inhibitorji |
| CA2531061A1 (en) * | 2003-07-02 | 2005-01-13 | Vertex Pharmaceuticals Incorporated | Pyrimidines useful as modulators of voltage-gated ion channels |
| WO2007109324A2 (en) | 2006-03-21 | 2007-09-27 | Xenon Pharmaceuticals, Inc. | Potent and selective nav 1.7 sodium channel blockers |
| US20080227799A1 (en) | 2006-07-11 | 2008-09-18 | Liotta Dennis C | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders |
| CA2687764A1 (en) * | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| CA2691003A1 (en) | 2007-06-26 | 2008-12-31 | Lexicon Pharmaceuticals, Inc. | Methods of treating serotonin-mediated diseases and disorders |
| WO2009010784A1 (en) | 2007-07-13 | 2009-01-22 | Astrazeneca Ab | New compounds 955 |
| WO2009091388A2 (en) | 2007-12-21 | 2009-07-23 | Progenics Pharmaceuticals, Inc. | Triazines and related compounds having antiviral activity, compositions and methods thereof |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| US8236880B2 (en) | 2008-04-23 | 2012-08-07 | Taylor Made Golf Company, Inc. | Compositions comprising an amino triazine and ionomer or ionomer precursor |
| US8633233B2 (en) | 2008-08-06 | 2014-01-21 | Hydra Biosciences, Inc. | Methods and compositions for treating anxiety |
| WO2010022055A2 (en) * | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| AU2011218167B2 (en) * | 2010-02-17 | 2014-07-10 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| DK2616465T3 (da) * | 2010-09-13 | 2016-02-01 | Novartis Ag | Triazin-oxadiazoler |
-
2011
- 2011-09-13 DK DK11757294.1T patent/DK2616465T3/da active
- 2011-09-13 JP JP2013527645A patent/JP2013537180A/ja active Pending
- 2011-09-13 PH PH1/2013/500473A patent/PH12013500473A1/en unknown
- 2011-09-13 WO PCT/EP2011/065868 patent/WO2012035023A1/en not_active Ceased
- 2011-09-13 HR HRP20160094TT patent/HRP20160094T1/hr unknown
- 2011-09-13 AU AU2011303978A patent/AU2011303978B2/en not_active Ceased
- 2011-09-13 PE PE2013000506A patent/PE20131377A1/es not_active Application Discontinuation
- 2011-09-13 EA EA201390381A patent/EA026132B1/ru not_active IP Right Cessation
- 2011-09-13 ES ES11757294.1T patent/ES2559449T3/es active Active
- 2011-09-13 MX MX2013002864A patent/MX2013002864A/es not_active Application Discontinuation
- 2011-09-13 PL PL11757294T patent/PL2616465T3/pl unknown
- 2011-09-13 CN CN2011800544823A patent/CN103221408A/zh active Pending
- 2011-09-13 HU HUE11757294A patent/HUE027256T2/en unknown
- 2011-09-13 RS RS20160045A patent/RS54544B1/sr unknown
- 2011-09-13 KR KR1020137009331A patent/KR101843600B1/ko not_active Expired - Fee Related
- 2011-09-13 SG SG2013016829A patent/SG188438A1/en unknown
- 2011-09-13 BR BR112013005889-7A patent/BR112013005889A2/pt not_active IP Right Cessation
- 2011-09-13 SI SI201130707T patent/SI2616465T1/sl unknown
- 2011-09-13 CA CA2812081A patent/CA2812081A1/en not_active Abandoned
- 2011-09-13 EP EP11757294.1A patent/EP2616465B1/en active Active
- 2011-09-13 NZ NZ608116A patent/NZ608116A/en not_active IP Right Cessation
- 2011-09-13 PT PT117572941T patent/PT2616465E/pt unknown
-
2013
- 2013-03-13 CL CL2013000685A patent/CL2013000685A1/es unknown
- 2013-03-13 CR CR20130111A patent/CR20130111A/es unknown
- 2013-03-13 CO CO13050505A patent/CO6690768A2/es unknown
- 2013-03-13 CU CU2013000036A patent/CU20130036A7/es unknown
- 2013-10-15 US US14/054,221 patent/US8895733B2/en not_active Expired - Fee Related
-
2014
- 2014-10-08 US US14/509,705 patent/US20150025057A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20160094T1 (hr) | 2016-02-26 |
| EA201390381A1 (ru) | 2013-08-30 |
| HUE027256T2 (en) | 2016-08-29 |
| AU2011303978A1 (en) | 2013-03-21 |
| KR20130105657A (ko) | 2013-09-25 |
| SI2616465T1 (sl) | 2016-02-29 |
| JP2013537180A (ja) | 2013-09-30 |
| DK2616465T3 (da) | 2016-02-01 |
| NZ608116A (en) | 2014-05-30 |
| US20140051676A1 (en) | 2014-02-20 |
| US20150025057A1 (en) | 2015-01-22 |
| PE20131377A1 (es) | 2013-11-30 |
| BR112013005889A2 (pt) | 2020-08-25 |
| CU20130036A7 (es) | 2013-05-31 |
| ES2559449T3 (es) | 2016-02-12 |
| US8895733B2 (en) | 2014-11-25 |
| AU2011303978B2 (en) | 2014-07-03 |
| EP2616465A1 (en) | 2013-07-24 |
| CR20130111A (es) | 2013-05-29 |
| EP2616465B1 (en) | 2015-11-04 |
| KR101843600B1 (ko) | 2018-03-29 |
| SG188438A1 (en) | 2013-05-31 |
| PH12013500473A1 (en) | 2013-05-06 |
| RS54544B1 (sr) | 2016-06-30 |
| PT2616465E (pt) | 2016-03-09 |
| CN103221408A (zh) | 2013-07-24 |
| EA026132B1 (ru) | 2017-03-31 |
| CA2812081A1 (en) | 2012-03-22 |
| CO6690768A2 (es) | 2013-06-17 |
| MX2013002864A (es) | 2013-08-29 |
| PL2616465T3 (pl) | 2016-04-29 |
| WO2012035023A1 (en) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| CR10694A (es) | Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y procedimientos de uso | |
| CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
| CL2007002207A1 (es) | Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
| DK1928438T3 (da) | Anvendelse af ibudilast til behandling af stofafhængighed | |
| CL2007003033A1 (es) | Compuestos derivados de benzoilamino heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la diabetes tipo ii. | |
| CL2013001141A1 (es) | Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c. | |
| ES2620754T3 (es) | Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores | |
| EA200970916A1 (ru) | Соединения 5,6-дигидро-1н-пиридин-2-она | |
| CL2012002716A1 (es) | Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica. | |
| MX384833B (es) | Inhibidores de tirosina quinasa de bruton | |
| EA201001230A1 (ru) | Пестицидные смеси | |
| CL2007002296A1 (es) | Compuestos derivados de imidazolina-2,4-dionas sustituidas con arilaminoalquilo; composicion farmaceutica; y uso del compuesto en el tratamiento del sindrome metabolico, diabetes, obesidad, dependencia de la nicotina, dependencia del alcohol, trastor | |
| CL2008000110A1 (es) | Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos. | |
| PE20170148A1 (es) | Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer | |
| EA201201623A1 (ru) | Лечение диабета 2 типа |